| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/10/2002 | WO2001037785A3 Novel methods and compositions involving opioids and antagonists thereof |
| 01/10/2002 | WO2001036472A3 Compositions and methods for regulating tumor-associated antigen expression |
| 01/10/2002 | WO2001034118A3 Solid dispersion pharmaceutical formulations |
| 01/10/2002 | WO2001028594A3 Tumor detection by imaging and therapy of tumors |
| 01/10/2002 | WO2001028542A3 Combination therapy including camptothecin |
| 01/10/2002 | WO2001026639A3 Pharmaceutical composition of ateglinide and another antidiabeticagent |
| 01/10/2002 | WO2001025410A3 DIAGNOSTIC PROBES AND THERAPEUTICS TARGETING uPA AND uPAR |
| 01/10/2002 | WO2000069794A3 Use of calcium-activated potassium channel-modulating agents |
| 01/10/2002 | WO2000055332A3 Human regulators of intracellular phosphorylation |
| 01/10/2002 | WO2000045800A3 Immunosurpressive effects of pteridine derivatives |
| 01/10/2002 | US20020004594 Phosphoramidates and methods therefor |
| 01/10/2002 | US20020004587 Antibody for use in the treatment of cancer; antitumor agents |
| 01/10/2002 | US20020004586 Prion-binding activity in serum and proteins |
| 01/10/2002 | US20020004581 Polypeptide; for use in te diagnosis and treatment of microorganismal infections; bactericides |
| 01/10/2002 | US20020004580 Polypeptide; for use in the diagnosis and treatment of microorganismal infections; bactericides |
| 01/10/2002 | US20020004531 Nitrone inhibition of cancer development |
| 01/10/2002 | US20020004514 Anticancer compound and enantiomer separation method useful for synthesizing said compound |
| 01/10/2002 | US20020004512 Sexual disorders |
| 01/10/2002 | US20020004510 Compounds for treating fibromyalgia and chronic fatigue syndrome |
| 01/10/2002 | US20020004503 Viricides |
| 01/10/2002 | US20020004502 Using taurolidine |
| 01/10/2002 | US20020004500 Drug mixture for cardiovascular disorders |
| 01/10/2002 | US20020004499 Mixture of antibiotics; variations of releasing profiles |
| 01/10/2002 | US20020004498 Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 01/10/2002 | US20020004497 Combination injection preparation |
| 01/10/2002 | US20020004495 Methods for stimulating bone formation |
| 01/10/2002 | US20020004492 Polypeptides; wound healing agent, antiinflammatory agent |
| 01/10/2002 | US20020004484 Topical anesthetic/opioid formulations and uses thereof |
| 01/10/2002 | US20020004482 Treatment of acute lung injury and fibrosis with antagonists of avbeta6 |
| 01/10/2002 | US20020004218 Bone disorders therapy |
| 01/10/2002 | US20020004209 Detecting modulators of transcription; incubate cell containing human androgen and estrogen receptors, preferential protein and modulator, monitor cell for adjustment in transcriptional activity |
| 01/10/2002 | US20020004208 Generating nicotine antibodies in situ |
| 01/10/2002 | US20020004194 Detecting modulators of proteins associated with ionic mobility; obtain cell, incubate with amyloid protein, monitor cells for reduced ionic mobility |
| 01/10/2002 | US20020004078 Composition and method for treating the effects of diseases and maladies |
| 01/10/2002 | US20020004047 DNA encoding a novel RG1 polypeptide |
| 01/10/2002 | US20020004046 Includes use of neutralizing antibody, high affinity antibodies, and viricide (ribavirin, amantadine, rimantadine, or a neuraminidase inhibitor); useful for controlling/treating respiratory syncytial virus in young children |
| 01/10/2002 | US20020004043 Cellular and animal models for diseases associated with altered mitochondrial function |
| 01/10/2002 | US20020004039 Stimulating proliferation of neural progenitor cells with epidermal growth factor binding polypeptide; directing migration of progeny to neurological injury sight; stimulating cell differentiation at injury |
| 01/10/2002 | US20020003179 Forming a dispersion of solid particles of a milled substrate in a fluid carrier comprising providing large size milling media and small size milling media, a conglomerate of solid comprising a substrate to be milled, milling, separating |
| 01/10/2002 | DE10029671A1 Biotransformation von biologisch aktiven Verindungen aus verschiedenen chemischen Stoffklassen mittels der Enzyme Laccase und Manganperoxidase Biotransformation of biologically active Verindungen from different classes of chemical substances by means of enzymes laccase and manganese peroxidase |
| 01/10/2002 | CA2630062A1 Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| 01/10/2002 | CA2416292A1 Transgenic mice containing targeted gene disruptions |
| 01/10/2002 | CA2415123A1 Novel fibroblast growth factors and nucleic acids encoding same |
| 01/10/2002 | CA2414995A1 Inhibitory pas domain protein (ipas) and screening methods related to angiogenesis and tumor progression |
| 01/10/2002 | CA2414881A1 Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| 01/10/2002 | CA2414672A1 Novel human serine-threonine kinase |
| 01/10/2002 | CA2414650A1 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 01/10/2002 | CA2414497A1 Isolated human ion channel proteins, nucleic acid molecules encoding human ion channel proteins, and uses thereof |
| 01/10/2002 | CA2414355A1 Amphipathic linear peptides and compositions containing same |
| 01/10/2002 | CA2414352A1 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
| 01/10/2002 | CA2413756A1 Dna encoding human serine protease d-g |
| 01/10/2002 | CA2413753A1 Antifungal compounds and methods of use |
| 01/10/2002 | CA2413715A1 Grf2-binding proteins and applications thereof |
| 01/10/2002 | CA2413262A1 B7-like molecules and uses thereof |
| 01/10/2002 | CA2413237A1 Alteration of cell membrane for new functions |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413166A1 Acid-modified arabinogalactan protein composition |
| 01/10/2002 | CA2413158A1 Ecm-related tumor marker |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2412845A1 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 01/10/2002 | CA2412839A1 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) |
| 01/10/2002 | CA2411692A1 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/10/2002 | CA2411386A1 Combination therapy for treatment of psychoses |
| 01/10/2002 | CA2410953A1 Adenylyl and guanylyl cyclases |
| 01/10/2002 | CA2410679A1 Secretion and trafficking molecules |
| 01/10/2002 | CA2407910A1 Antibodies that immunospecifically bind to blys |
| 01/09/2002 | EP1170594A2 Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2 |
| 01/09/2002 | EP1170591A2 Methods for identifying combinations of entities as therapeutics |
| 01/09/2002 | EP1170289A2 Retroviral protease inhibiting compounds |
| 01/09/2002 | EP1170020A1 Patches for external use |
| 01/09/2002 | EP1170017A1 Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition |
| 01/09/2002 | EP1170013A1 Drugs, foods, drinks and feeds containing cocoa component |
| 01/09/2002 | EP1169644A1 Method to type prion proteins |
| 01/09/2002 | EP1169475A1 Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy |
| 01/09/2002 | EP1169469A1 Human colon cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP1169459A1 Dsp-9 dual-specificity map kinase phosphatase |
| 01/09/2002 | EP1169448A1 Tumor necrosis factor homologs and nucleic acids encoding the same |
| 01/09/2002 | EP1169443A1 REAGENTS AND METHODS FOR IDENTIFYING AND MODULATING EXPRESSION OF GENES REGULATED BY p21 |
| 01/09/2002 | EP1169442A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2002 | EP1169440A1 48 human secreted proteins |
| 01/09/2002 | EP1169352A1 Erythropoietin receptor antibodies |
| 01/09/2002 | EP1169350A2 Human obesity protein binding protein-2 homolog compositions and uses thereof |
| 01/09/2002 | EP1169346A1 48 human secreted proteins |
| 01/09/2002 | EP1169340A1 Lantibiotic |
| 01/09/2002 | EP1169339A1 Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease |
| 01/09/2002 | EP1169322A1 Pyridoxal analogues for vitamin b-6 disorders |
| 01/09/2002 | EP1169313A2 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof |
| 01/09/2002 | EP1169064A2 Method of detecting endometriosis |
| 01/09/2002 | EP1169060A1 Sodium channel blocker compositions and the use thereof |
| 01/09/2002 | EP1169058A1 Insulin-like growth factor binding protein-4 protease |
| 01/09/2002 | EP1169056A1 Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseases |
| 01/09/2002 | EP1169054A2 Products and methods for treating ptp lar related diseases |
| 01/09/2002 | EP1169049A2 Treatment of myeloma bone disease with proteasomal and nf-kappa-b activity inhibitors |
| 01/09/2002 | EP1169045A2 Immunomodulating polymers |
| 01/09/2002 | EP1169043A1 Use of estrogens and delta-gonadien-21-ol-3,20-diones |
| 01/09/2002 | EP1169042A1 Dibenzo-azepine derivatives as alpha v integrin receptor antagonists |
| 01/09/2002 | EP1169038A1 Cyclic protein tyrosine kinase inhibitors |
| 01/09/2002 | EP1169036A2 Anti-viral uses of leflunomide products |
| 01/09/2002 | EP1169035A2 Anti-tumor synergetic composition |